Open AccessAripiprazole-induced obsessive–compulsive symptoms
Author(s) -
Dilshafisa,
Anil Kakunje
Publication year - 2022
Publication title -
industrial psychiatry journal/industrial psychiatry journal
Language(s) - Uncategorized
Resource type - Journals
eISSN - 0976-2795
pISSN - 0972-6748
DOI - 10.4103/ipj.ipj_182_20
Subject(s) - aripiprazole , risperidone , olanzapine , clozapine , partial agonist , adverse effect , schizophrenia (object oriented programming) , antipsychotic , extrapyramidal symptoms , psychology , atypical antipsychotic , quetiapine , medicine , psychiatry , agonist , receptor
Aripiprazole is a novel antipsychotic with a unique pharmacological profile as a dopamine partial agonist. It is indicated for treatment of schizophrenia and bipolar disorder. This new antipsychotic has low rate of extrapyramidal side effects, metabolic changes and no significant adverse effect on serum prolactin concentration. In addition,it is not associated with significant weight gain like other atypical antipsychotics. As a reason, when other antipsychotics cause these adverse events, it's not uncommon to switch to Aripiprazole. Obsessive compulsive symptoms have been untoward sequel of a few second-generation antipsychotics. Among the second generation antipsychotics Clozapine, Olanzapine, and Risperidone are the most prominent agents associated with these sequelae, according to case reports. More recently, a handful of case reports indicated development of Obsessive-compulsive symptoms with Aripiprazole. We report a case that exhibited similar unexpected adverse effects after administration of Aripiprazole. Keywords: Aripiprazole, Second generation antipsychotics, Obsessive-compulsive symptoms (OCS).